JP2023533871A - 免疫療法のためのａｐｃ標的化単位 - Google Patents

免疫療法のためのａｐｃ標的化単位 Download PDF

Info

Publication number
JP2023533871A
JP2023533871A JP2023503113A JP2023503113A JP2023533871A JP 2023533871 A JP2023533871 A JP 2023533871A JP 2023503113 A JP2023503113 A JP 2023503113A JP 2023503113 A JP2023503113 A JP 2023503113A JP 2023533871 A JP2023533871 A JP 2023533871A
Authority
JP
Japan
Prior art keywords
fusion polypeptide
unit
apc
expression
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533871A5 (https=
Inventor
レヌ，ビアギッテ
バルリオ カルボ，マリナ
ブンゴー セレンセン，アナス
チューエセン，クリスティアン
クリンゲルム，イェンス
フリース，スティーネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evaxion A/S
Original Assignee
Evaxion A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evaxion A/S filed Critical Evaxion A/S
Publication of JP2023533871A publication Critical patent/JP2023533871A/ja
Publication of JP2023533871A5 publication Critical patent/JP2023533871A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001121—Receptors for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023503113A 2020-07-14 2021-07-14 免疫療法のためのａｐｃ標的化単位 Pending JP2023533871A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20185743.0 2020-07-14
EP20185743 2020-07-14
EP20207526 2020-11-13
EP20207526.3 2020-11-13
EP21171319 2021-04-29
EP21171319.3 2021-04-29
PCT/EP2021/069582 WO2022013277A1 (en) 2020-07-14 2021-07-14 Apc targeting units for immunotherapy

Publications (2)

Publication Number Publication Date
JP2023533871A true JP2023533871A (ja) 2023-08-04
JP2023533871A5 JP2023533871A5 (https=) 2024-07-19

Family

ID=79555093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503113A Pending JP2023533871A (ja) 2020-07-14 2021-07-14 免疫療法のためのａｐｃ標的化単位

Country Status (6)

Country Link
US (1) US20230355733A1 (https=)
EP (1) EP4181949A1 (https=)
JP (1) JP2023533871A (https=)
AU (1) AU2021307553A1 (https=)
CA (1) CA3183951A1 (https=)
WO (1) WO2022013277A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023023260A2 (pt) 2021-05-10 2024-01-30 Nykode Therapeutics ASA Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica
US20250304626A1 (en) 2021-05-26 2025-10-02 Evaxion Biotech A/S Vaccination targeting intracellular pathogens
CN114106207B (zh) * 2022-01-24 2022-04-26 诺未科技（北京）有限公司 Ccl5的用途
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532315A (ja) * 2002-05-10 2005-10-27 イネックス ファーマシューティカルズ コーポレイション メチル化免疫刺激性オリゴヌクレオチド及びその使用方法
US20180161412A1 (en) * 2016-12-14 2018-06-14 Cyvax, Inc. Extended protection protein vaccines against infectious agents
JP2019505512A (ja) * 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
WO2020142752A1 (en) * 2019-01-04 2020-07-09 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
JP2023521722A (ja) * 2020-04-07 2023-05-25 エヴァクシオン・バイオテック・アクティエセルスカブ Ａｐｃ標的化単位を用いたネオエピトープ免疫療法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013224658A1 (en) * 2006-07-21 2013-09-19 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
JP2013532971A (ja) * 2010-06-25 2013-08-22 バッシボディ アクスイェ セルスカプ ホモ二量体タンパク質コンストラクト
AU2012311238A1 (en) * 2011-09-23 2014-04-17 University Of Oslo Vaccibodies targeted to cross-presenting dendritic cells
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
CA3060569A1 (en) 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
WO2018201017A1 (en) * 2017-04-27 2018-11-01 Washington University Dendritic cell targeted adenovirus for vaccination
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532315A (ja) * 2002-05-10 2005-10-27 イネックス ファーマシューティカルズ コーポレイション メチル化免疫刺激性オリゴヌクレオチド及びその使用方法
JP2019505512A (ja) * 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
US20180161412A1 (en) * 2016-12-14 2018-06-14 Cyvax, Inc. Extended protection protein vaccines against infectious agents
WO2020142752A1 (en) * 2019-01-04 2020-07-09 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
JP2023521722A (ja) * 2020-04-07 2023-05-25 エヴァクシオン・バイオテック・アクティエセルスカブ Ａｐｃ標的化単位を用いたネオエピトープ免疫療法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IMMUNOLOGY, vol. 117, JPN6025027800, 2006, pages 419 - 430, ISSN: 0005637066 *
THE JOURNAL OF IMMUNOLOGY, vol. 169 (6), JPN6025027802, 2002, pages 2925 - 2936, ISSN: 0005637067 *
VACCINES, vol. 1, JPN6025027799, 2013, pages 444 - 462, ISSN: 0005637065 *

Also Published As

Publication number Publication date
US20230355733A1 (en) 2023-11-09
WO2022013277A1 (en) 2022-01-20
AU2021307553A1 (en) 2023-02-16
CA3183951A1 (en) 2022-01-20
EP4181949A1 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
JP2023533871A (ja) 免疫療法のためのａｐｃ標的化単位
JP7665205B2 (ja) ネオエピトープをコードするコンストラクトを用いた核酸ワクチン接種
JP5127224B2 (ja) 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法
CN107050440B (zh) 疫苗组合物和其使用方法
JP2022017499A (ja) 治療用抗癌ネオエピトープワクチン
US9885017B2 (en) Compositions and methods to immunize against hepatitis C virus
JP2020505403A (ja) 免疫療法のためのコア／シェル構造プラットホーム
JP2023521722A (ja) Ａｐｃ標的化単位を用いたネオエピトープ免疫療法
CN107847567B (zh) 方法
ES3035198T3 (en) Cpg amphiphiles and uses thereof
Takashima et al. Dendritic cells in genetic immunization
Daemi et al. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model
US20230072079A1 (en) Nucleic acid vaccination using neo-epitope encoding constructs
Lemieux Technological advances to increase immunogenicity of DNA vaccines
JP7707161B2 (ja) 合成ｒｉｇ－ｉ様受容体アゴニスト
Meshkat et al. Strong immune responses induced by a DNA vaccine containing HPV16 truncated E7 C-terminal linked to HSP70 gene
Babiuk et al. DNA vaccination: a simple concept with challenges regarding implementation
Du et al. The rise of mRNA therapeutic vaccines
Schmidt et al. MIDGE vectors and dSLIM immunomodulators: DNA-based molecules for gene therapeutic strategies
US20120219591A1 (en) Use of vectors expressing intracellular polynucleotide binding proteins as adjuvants
ES2330182A1 (es) Vacuna contra el virus de papiloma humano.

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240708

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260414